Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Renalytix ( (GB:RENX) ) has shared an announcement.
Renalytix has released new data at the National Kidney Foundation Spring Clinical Meeting, demonstrating the impact of its KidneyIntelX test on the prescription rates of SGLT2 inhibitors. The study shows that the test significantly increases targeted use of these inhibitors among patients at moderate or high risk of disease progression, highlighting its utility in improving patient care and outcomes. This development underscores the importance of early risk assessment in chronic kidney disease management, potentially influencing treatment protocols and enhancing Renalytix’s position in the healthcare industry.
Spark’s Take on GB:RENX Stock
According to Spark, TipRanks’ AI Analyst, GB:RENX is a Underperform.
Renalytix’s overall stock score is low due to severe financial challenges, including declining revenues, high operating losses, and solvency issues. Although recent corporate events show promise with revenue growth and strategic investor interest, the technical analysis and valuation remain weak, impacting the stock’s appeal.
To see Spark’s full report on GB:RENX stock, click here.
More about Renalytix
Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to improve patient outcomes. The company offers kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test for early-stage risk assessment in chronic kidney disease, primarily in the United States.
YTD Price Performance: 13.75%
Average Trading Volume: 404
Technical Sentiment Signal: Buy
Current Market Cap: $35.11M
For detailed information about RENX stock, go to TipRanks’ Stock Analysis page.